Pub. Date : 2013 Mar
PMID : 22960998
7 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | The effect of genetic polymorphisms in UGT2B15 on the pharmacokinetic profile of sipoglitazar, a novel anti-diabetic agent. | sipoglitazar | UDP glucuronosyltransferase family 2 member B15 | Homo sapiens |
| 2 | Subjects homozygous for the UGT2B15 D85Y variant (UGT2B15*2/*2) were exposed to greater plasma concentrations of sipoglitazar than subjects homozygous for the wild-type allele UGT2B15*1/*1 (3.26-fold higher) or heterozygous allele UGT2B15*1/*2 (2.16-fold higher). | sipoglitazar | UDP glucuronosyltransferase family 2 member B15 | Homo sapiens |
| 3 | Subjects homozygous for the UGT2B15 D85Y variant (UGT2B15*2/*2) were exposed to greater plasma concentrations of sipoglitazar than subjects homozygous for the wild-type allele UGT2B15*1/*1 (3.26-fold higher) or heterozygous allele UGT2B15*1/*2 (2.16-fold higher). | sipoglitazar | UDP glucuronosyltransferase family 2 member B15 | Homo sapiens |
| 4 | Subjects homozygous for the UGT2B15 D85Y variant (UGT2B15*2/*2) were exposed to greater plasma concentrations of sipoglitazar than subjects homozygous for the wild-type allele UGT2B15*1/*1 (3.26-fold higher) or heterozygous allele UGT2B15*1/*2 (2.16-fold higher). | sipoglitazar | UDP glucuronosyltransferase family 2 member B15 | Homo sapiens |
| 5 | Subjects homozygous for the UGT2B15 D85Y variant (UGT2B15*2/*2) were exposed to greater plasma concentrations of sipoglitazar than subjects homozygous for the wild-type allele UGT2B15*1/*1 (3.26-fold higher) or heterozygous allele UGT2B15*1/*2 (2.16-fold higher). | sipoglitazar | UDP glucuronosyltransferase family 2 member B15 | Homo sapiens |
| 6 | CONCLUSIONS: These results indicate that sipoglitazar clearance is substantially modified by UGT2B15 enzyme variants, with higher exposure observed in the UGT2B15*2/*2 genotype group. | sipoglitazar | UDP glucuronosyltransferase family 2 member B15 | Homo sapiens |
| 7 | CONCLUSIONS: These results indicate that sipoglitazar clearance is substantially modified by UGT2B15 enzyme variants, with higher exposure observed in the UGT2B15*2/*2 genotype group. | sipoglitazar | UDP glucuronosyltransferase family 2 member B15 | Homo sapiens |